Merck hands back preclinical Parkinson's disease assets to Addex
This article was originally published in Scrip
Addex Pharmaceuticals, the Swiss biotech, has found itself once again a potential innocent bystander in the integration of Merck & Co and Schering-Plough. On 2 September, just after the markets had closed, Addex announced that Merck had opted not to continue developing orally available positive allosteric modulators (PAM) targeting the metabotropic glutamate receptor 4 (mGluR4) as potential treatments for Parkinson's disease and other undisclosed indications.
You may also be interested in...
Prexton Therapeutics has the only mGluR4-targeting drug candidate in clinical testing, after a number of big pharma dropped preclinical programs. The company has just secured €29m to fund two Phase II trials.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.